Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Abstract

Two genes (low angiotensinogen and high HLA-class II expression) were predictive for bevacizumab response and were included in a predictive model for response. This model can be used in clinical practice to identify patients who will benefit from bevacizumab combination therapy.